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Abstract 
The FGF19-FGFR4-βKlotho (KLB) pathway plays an important role in the regulation of bile acid (BA) 
homeostasis. Aberrant activation of this pathway has been described in the development and progression 
of a subset of liver cancers including hepatocellular carcinoma (HCC), establishing FGFR4 as an attractive 
therapeutic target for such solid tumors. FGF401 is a highly selective FGFR4 kinase inhibitor being 
developed for HCC, currently in Phase I/II clinical studies. In preclinical studies in mice and dogs, single 
or repeated doses of FGF401 led to induction of Cyp7a1 in the liver, the rate-limiting enzyme in BA 
biosynthesis, and elevation of its peripheral marker 7alpha-hydroxy-4-cholesten-3-one (C4), resulting in 
increased BA pool size, decreased serum cholesterol and diarrhea in dogs. FGF401 was also associated 
with increases of serum aminotransferases, primarily alanine aminotransferase (ALT), in mice and dogs in 
the absence of any observable adverse histopathological findings in the liver, or in any other organs. We 
hypothesized that the increase in ALT could be secondary to increased BAs and conducted an investigative 
study in dogs with FGF401 and co-administration of the BA sequestrant cholestyramine (CHO) to test this 
hypothesis. Here we show that co-administration of CHO with FGF401 prevented and reversed FGF401-
related increases in ALT in dogs in parallel to its ability to reduce BAs in the circulation. BA profile analysis 
revealed that effects of BA sequestration were most pronounced for secondary BAs of high hydrophobicity. 
Indeed, correlation analysis showed that FGF401-mediated increases in ALT strongly correlated with 
increases in TLCA and TDCA, the major secondary BAs in dog plasma, making a mechanistic link between 
ALT elevation and changes in BA pool hydrophobicity plausible. These data therefore confirm our 
hypothesis that the increase in ALT with FGF401 is likely secondary to BAs increases and can be prevented 
by CHO. In human subjects, CHO may offer the potential to mitigate elevations in serum aminotransferases 
that are caused by targeted FGFR4 inhibition and elevated intracellular BA levels, in addition to its 
established role in diarrhea management. 
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Introduction 
The role of FGF19/FGFR4/KLB in bile acid homeostasis. FGF401 is a highly selective and potent FGFR4 
inhibitor through binding of the kinase domain adenosine triphosphate (ATP) binding-site of FGFR4, a 
member of the fibroblast growth factor receptor (FGFR) family. FGF19, which signals through FGFR4 and 
its co-receptor βKlotho (KLB), both commonly expressed in the liver (1), plays a key role in the regulation 
of bile acid (BA) homoeostasis (2) and has been associated with liver tumorigenesis (3), leading to a rising 
interest in inhibiting the FGF19-FGFR4 signaling axis in hepatocellular carcinoma (HCC) (4, 5).  
The expression of FGF19 is induced in the ileum in response to BAs released into the intestinal lumen after 
feeding. Intestinally reabsorbed BAs activate the nuclear transcription factor farnesoid X receptor (FXR) 
within enterocytes, which controls the transcriptional regulation of FGF19. FGF19 is released into the portal 
vein and circulates to the liver where FGFR4 and KLB are highly co-expressed. Binding of FGF19 to the 
FGFR4-KLB complex leads to activation of a signal transduction cascade within the liver that results in the 
repression of Cyp7a1 transcription, the rate-limiting enzyme for BA synthesis (2). Cyp7a1 converts 
cholesterol to 7-alpha-hydroxycholesterol, which is further oxidized to 7alpha-hydroxy-4-cholesten-3-one 
(C4), a stable BA intermediate and peripheral blood marker for hepatic Cyp7a1 activity (6). The pathway 
subsequently drives the formation of the two primary BAs cholic acid (CA) and chenodeoxycholic acid 
(CDCA) as illustrated in Figure 1 (7). Thus, BA synthesis represents the major catabolic pathway of 
cholesterol degradation. Within the hepatocyte, BAs are conjugated with glycine (G) or taurine (T) and 
transported into the bile canaliculi by BA transporters such as BSEP. In dogs, T-conjugation predominates, 
while in non-human primates and humans G-conjugated BAs are predominant (8). Bile fluid, which 
contains high millimolar concentrations of Bas, is subsequently stored in the gallbladder before it is released 
into the intestine upon food intake to facilitate lipid digestion. The filling of the gallbladder is regulated by 
FGF19, highlighting its importance in BA homeostasis (9). Within the intestine, the primary BAs CA and 
CDCA are converted by the intestinal microflora to the secondary BAs deoxycholic acid (DCA) and 
lithocholic acid (LCA), respectively, and to a minor extent to ursodeoxycholic acid (UDCA). The secondary 
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BAs DCA and LCA are generally more hydrophobic (due to the removal of a hydroxy group) and 
physiologically more potent as agonists of the BA receptors FXR or TGR5 (10-12), but also more cytotoxic 
compared to CA (13) due to the higher potential to disturb membranes integrity and mitochondrial function 
(14). The different aspects of BA toxicity in the context of liver homeostasis and drug induced liver injury 
is discussed and reviewed elsewhere (8). The majority of intestinal BAs are reabsorbed by enterocytes, 
released into the portal vein, and taken up by the liver via the sinusoidal membrane. Only small amounts of 
BAs escape this enterohepatic cycling and are excreted via the feces, accounting for approximately 10 to 
20 % loss per day (15, 16). 
Cholestyramine as a BA sequestrant. The BA sequestrant cholestyramine (CHO) is a strong ion exchange 
resin that binds BAs in the intestine and forms insoluble complexes. Intestinal binding of BAs by CHO 
prevents BA reabsorption and leads to enhanced BA excretion by the feces. CHO is therefore used in the 
clinic for management of bile acid diarrhea (17). In addition, it is also indicated to treat 
hypercholesterolemia due to its ability to lower serum cholesterol levels by increasing the conversion of 
hepatic cholesterol to BAs via indirect induction of hepatic Cyp7a1 (18). Induction of hepatic Cyp7a1 
occurs secondary to CHO mediated intestinal depletion of BAs and subsequent activation of the endocrine 
FXR-FGF19-FGFR4- Cyp7a1 pathway (16).  
Safety considerations for FGFR4 pathway inhibition. FGFR4 knockout mice have a larger BA pool with 
increased excretion of BAs, enhanced expression of Cyp7a1, BA-depleted gall bladders (19, 20), and 
hypercholesterolemia (21). Similar findings are reported for FGF15 knockout mice (mouse FGF19 
ortholog) (22) and KLB knockout mice (23). Liver toxicity characterized by single cell necrosis and 
increased bilirubin, severe diarrhea and decreased food consumption have previously been reported in 
cynomologus monkeys given single or repeated doses of an anti FGF19 monoclonal antibody, and were 
presumably secondary to increased BAs (24). 
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Single or repeated doses of FGF401 in dogs led to induction of Cyp7a1 in the liver resulting in increased 
plasma and fecal BA content, and was associated with decreased serum cholesterol, diarrhea, and elevation 
of serum ALT in the absence of adverse histopathological findings in the liver, or in other organs that could 
be a source of ALT. In order to address if ALT perturbation could have been secondary to BA increases 
and its potential mitigation we conducted an investigative study in dogs co-treated with FGF401 and the 
BA sequestrant CHO to address this hypothesis. 
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Results 
FGF401 induced bile acid biosynthesis, increased serum ALT and decreased cholesterol in the 4-week dog 
toxicity study. Repeated oral (gavage) administration of FGF401 to beagle dogs for 4 weeks at dose levels 
of 5, 15 and 45 mg/kg/day was overall well tolerated with only limited, dose-dependent in-life signs such 
as salivation, vomiting, and liquid or soft feces.  
In the liver, the treatment with FGF401 resulted in a significant increase in Cyp7a1 mRNA levels (Figure 
2A) which confirms blockage of the FGFR4 receptor by FGF401. The lack of a clear dose-response 
relationship after 4 weeks of treatment suggests full target saturation and signaling pathway activation 
already at the 5 mg/kg/day dose with no further enhancement at higher doses. Treatment with FGF401 at 
doses ≥ 5 mg/kg/day led to increased levels of C4 in plasma starting between 3 to 7 hours post-dose on day 
1 (Figure 2B). The increases in plasma C4 concentrations were sustained and more pronounced after 4 
weeks of treatment (Figure 2C). The changes in circulating C4 were consistent with the induction of hepatic 
Cyp7a1 mRNA by RT qPCR both after single (data not shown) and repeated dose administration. 
Analysis of the BA profiles showed that the major BA components in control dog plasma were taurine-
conjugated TCA (39%), TCDCA (25%), TDCA (21%), TLCA (4%) and unconjugated CA (7%) (Figure 
3A), whereas in control dog feces, the unconjugated secondary BAs DCA (61%) and LCA (28%) were 
most abundant, followed by lower amounts of the unconjugated primary BAs CA (5%) and CDCA (3%) 
(Figure 3B). 
Treatment at doses ≥ 5 mg/kg/day FGF401 for 4 weeks resulted in increases in the major BA components 
in plasma (Figure 3C), which was already seen after single administration at the higher doses, yet less 
pronounced (data not shown). Consistent with the FGF401-related increases in plasma BAs, the 
corresponding unconjugated primary and secondary BAs were also increased in fecal samples upon 
treatment (Figure 3D). Taken together, the data indicated a general increase in BA pool size upon FGF401 
treatment as a consequence of increased BA biosynthesis due to FGFR4 inhibition. 
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Dogs treated with FGF401 showed mildly decreased total cholesterol concentrations in serum (Figure 4A, 
both high-density and low-density lipoprotein cholesterol) and minimally to moderately (1.5- 5.6 fold) 
increased serum alanine aminotransferase (ALT) activity at all doses (Figure 4B). Effects on ALT activity 
and cholesterol concentrations were more apparent from treatment day 8, did not become progressively 
more severe over time and exhibited reversibility at the end of the 4-week treatment-free phase. Minimal 
increases in serum aspartate aminotransferase (≤ 1.7 fold, Figure 4C) in individual animals were also noted, 
particularly in those with the highest levels of ALT. Despite the increase in ALT, there were no adverse 
histopathological findings in the liver or in any other organs. While the occurrence of liquid/soft feces and 
the decrease in serum cholesterol were likely the consequence of increases in BA biosynthesis, pool size 
and intestinal BA content (16, 25), the cause for the transient increases in ALT without histopathological 
correlate remained undetermined in the 4-week toxicity study.  
Investigative dog study with FGF401 treatment and co-administration of cholestyramine 
The investigative dog study was designed in a way to address whether the FGF401-mediated ALT increase 
was secondary to increases in BAs and could be prevented and reversed by co-administration of the BA 
sequestrant CHO. A crossover study design with different phases and washout periods was applied similarly 
to a clinical setting in order to increase the statistical power and identify non-, weak-, or strong responders, 
and follow up on the time-course of FGF401-induced effects with and without CHO intervention (Figure 
5). FGF401 was administrated at a dose of 5 mg/kg/day, and CHO at a dose of 5 grams per animal 
approximately 2 hours after FGF401 administration, both by oral gavage. In an initial feasibility study phase 
the effects of CHO administration on tolerability and FGF401 exposure profile were investigated. However, 
CHO was well tolerated and did not compromise the absorption or change the exposure profile of FGF401 
(data not shown). 
Cholestyramine mitigates and reverses FGF401 mediated increases in ALT. As shown in Figure 6, the 
treatment with FGF401 alone caused minimal to moderate increases in serum ALT (≤ 4.3 fold), whereas 
co-administration of FGF401 with CHO did not result in increases in ALT levels. Furthermore, ALT levels 
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decreased relatively quickly to pretest values when FGF401 administration was discontinued or by adding 
CHO to dogs being treated with FGF401. In contrast, stopping administration of CHO and continuing 
FGF401 administration resulted in an ALT increasing trend.  
Cholestyramine prevents FGF401 mediated increases in plasma BA by increased fecal excretion. As 
expected, the treatment with the BA sequestrant CHO led to increased fecal excretion of BAs as confirmed 
by the increased BA content in feces (Figure 7A), and decreased the BA concentrations in plasma (Figure 
8). This effect was most pronounced for the hydrophobic secondary BAs DCA and LCA in feces and their 
corresponding taurine-conjugates TDCA and TLCA in plasma (Figure 7B). Consistent with our observation 
in the 4-week dog study, treatment with FGF401 alone resulted in increases in plasma BAs, driven both by 
primary and secondary BAs (Figure 8). When FGF401 was co-administered with CHO, plasma BA 
concentrations remained comparable to untreated controls or were even decreased (Figure 8A), this effect 
being more pronounced for the secondary BAs TDCA and TLCA (Figure 8C). When FGF401 
administration was discontinued or when CHO was co-administered to dogs being treated with FGF401, 
increased plasma BA levels decreased relatively quickly to or below untreated control values. Thus, the 
FGF401-mediated increases in plasma BAs could be mitigated and reversed by co-treatment with CHO, 
overall in a similar way as CHO was able to mitigate and reverse FGF401-mediated increases in serum 
ALT. 
Potential association between hydrophobic BAs and ALT increase. Correlation analysis (TIBCO Spotfire 
Linear Regression) at peak ALT levels revealed that the FGF401-mediated increase in serum ALT 
correlated best with plasma BAs of high hydrophobicity, such as TLCA (study day 14: r2 = 0.79, p<0.001; 
study day 38: r2 = 0.83, p<0.0001), TDCA (study day 14: r2 = 0.82, p<0.0001), the sum of these secondary 
BAs (study day 14: r2 = 0.82, p<0.0001; study day 38: r2 = 0.57, p<0.01), and the ratio of hydrophobic to 
polar BAs (sum of TLCA, TDCA, TCDCA divided by sum of TCA, CA; study day 14: r2 = 0.72, p<0.001; 
study day 38: r2 = 0.73, p<0.001). Consistently, a principal component analysis over all data points of the 
study also showed that plasma TLCA and TDCA showed a higher degree of correlation with ALT elevation 
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as compared to plasma TCDCA and TCA. These data therefore suggest a potential prominent role of 
hydrophobic, particularly secondary BAs in the mechanism of ALT elevation, and thus of the 
hydrophobicity of the BA pool. The secondary BAs are formed in the intestine by the microbiome at high 
abundance, and were also the ones most affected by the treatment with CHO. 
Effect of FGF401 and cholestyramine on cholesterol and C4.  
As shown in Figure 9A, treatment with FGF401 or CHO resulted in decreased serum total cholesterol 
concentrations, which quickly reversed to pretest levels upon treatment discontinuation. Consistent with 
our data from the 4-week toxicity study, treatment of dogs with FGF401 increased plasma C4 
concentrations, which became apparent after the first administration and appeared to plateau after 6 to 7 
days of repeated daily dosing (Figure 9B). As expected, when CHO was administrated alone in the first 
phase of the study, plasma C4 concentrations increased as well, indicating induction of hepatic Cyp7a1 
activity by the CHO treatment. When FGF401 was co-administered with CHO, plasma C4 concentrations 
increased further compared to FGF401 or CHO administration alone, which resulted in an additional 
elevation of C4 levels.  
Analysis of miR-122 in plasma as marker for hepatocellular injury. To investigate whether the liver might 
be the source of FGF401 mediated ALT elevation despite the lack of observable histopathological changes, 
exploratory miR-122 analysis was conducted in plasma as a biomarker for hepatic injury. Overall, 
circulating miR-122 levels were highly variable over the course of the study. The treatment with FGF401 
did not result in a consistent change in plasma miR-122 with the exception of two individual animals, which 
showed minimal to moderate increases in miR-122 when treated with FGF401 alone (study days 25 to 38), 
followed by a trend towards a decrease after co-treatment with CHO (Figure 10). The highest level of miR-
122 and ALT was seen in one out of these two animals, suggesting a hepatocellular origin of the ALT 
increase in that dog. Otherwise, there was no clear correlation between FGF401-induced ALT elevation 
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and changes in miR-122, although miR-122 appeared slightly more elevated in FGF401 treated animals 
than with FGF401-CHO combination. 
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Discussion 
Inhibition of the FGF19/FGFR4/KLB pathway is a promising target to treat patients with HCC, but is 
generally associated with modulation of BA homeostasis and increased BA pool size (4). Indeed, we 
showed that blockage of the FGFR4 receptor by the antagonist FGF401 led to upregulation of Cyp7a1 
mRNA in the liver, increased BA biosynthesis and BA content in plasma and feces in mice and dogs. The 
treatment with FGF401 was also associated with transient, minimal to mild increases in serum ALT without 
observable adverse histopathological findings in the liver or in any other tissues, making the cause of the 
ALT elevation unclear. We therefore sought to determine whether the FGF401-mediated increases in ALT 
were secondary to BA increases and conducted an investigative study in dogs with FGF401 treatment and 
co-administration of the BA sequestrant CHO. CHO administration itself did not affect levels of ALT in 
dogs in the investigative study, which was tested in the initial phase of the study in view of some clinical 
reports in healthy volunteers associating CHO treatment with increases in ALT (26-28). No treatment-
related effects on mortality/moribundity, clinical signs, body weight or food consumption parameters were 
noted at any dose or combination of doses with FGF401 and CHO. The lower levels of serum total 
cholesterol with FGF401 have also been noted in the 4-week dog study with daily dosing of FGF401. In 
addition, decreases in serum total cholesterol were observed in dogs treated with CHO alone, which is an 
anticipated effect of intestinal sequestration of BAs (18). In both cases, the mechanism behind the reduction 
in serum cholesterol is likely increased BA synthesis in the liver, which leads to increased consumption and 
subsequent depletion of hepatic cholesterol and in turn to increased cholesterol uptake from the circulation 
(16). Consistently, plasma C4 levels were increased in dogs treated with FGF401 both in the 4-week and 
in the investigative dog study, indicating FGFR4 antagonism with subsequent induction of hepatic Cyp7a1 
and BA biosynthesis. Thus, circulating C4 appears to be a suitable pharmacodynamic marker of FGFR4 
inhibition. However, CHO administration alone induced increases in plasma C4 as well, indicating hepatic 
induction of Cyp7a1 secondary to intestinal BA adsorption to the resin and increased excretion, which 
prevents activation of the endocrine FXR/FGF19/FGFR4/KLB/Cyp7a1 pathway (16). Consequently, C4 
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needs to be considered carefully [interpreted with caution?] as a surrogate marker for the 
pharmacodynamic response when FGF401 is co-administered with CHO in patients. 
FGF401-mediated increases in serum ALT were directly modified by co-administration of CHO. Indeed, 
co-administration of FGF401 and CHO prevented an increase in ALT, whereas administration of FGF401 
alone caused increased ALT levels up to approximately 4-fold in single animals compared to baseline. 
Following the same time-course, FGF401 administration alone increased plasma BAs concentrations due 
to increased biosynthesis paralleling the elevation in ALT, which was prevented and reversed by co-
administration with CHO. CHO binds BAs within the intestine, prevents its absorption and leads to 
increased fecal excretion as shown by the increased BA content in feces, which in turn decreased BAs in 
the circulation and reversed FGF401-related increases. Our results therefore demonstrate that lowering the 
amount of free BAs in the intestine by CHO can prevent both FGF401 mediated increases in circulating 
BAs and ALT. In the ongoing clinical trial with FGF401 in HCC patients in whom CHO is used for 
management of diarrhea, we have observed a trend towards lower levels of serum aminotransferases in 
patients given CHO. These clinical data, while early and limited, together with the results of our 
investigative dog study, suggest that CHO may have the potential to mitigate transaminase increases in the 
clinic in instances where BAs may be involved in ALT elevation. 
By investigating the potential associations between individual BA components and changes in ALT 
throughout the course of the investigative study, it appeared that the secondary BAs TDCA, TLCA, and 
thus the increased hydrophobicity of the BA pool, were strongly associated with increases in ALT. 
Secondary BAs are formed in the intestine by the microbiome (29), are generally more hydrophobic 
compared to primary BAs, and were strongly reduced in the circulation by the treatment with CHO. These 
hydrophobic BAs are also the ones with higher potency on BA receptors such as FXR or TGR5 (10-12), 
and exhibit higher cytotoxicity compared to the more polar ones (30) due to a higher potential to disturb 
membrane integrity and mitochondrial function (14). Thus, a mechanistic link between the FGF401-
mediated elevation in ALT and increased BAs, particularly of those with high hydrophobicity, appears 
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plausible and could involve various mechanisms including direct BA induced hepatocyte toxicity. 
However, a direct hepatotoxic effect of BAs on the liver as a potential cause for FGF401-mediated ALT 
elevation was not supported by our data based on the absence of histopathological observations in the 4-
week dog toxicity study. 
To further investigate the origin of ALT elevations in the non-terminal investigative dog study, analysis of 
circulating miR-122 as an exploratory biomarker for hepatic injury was conducted (31). Although miR-122 
appeared slightly higher in FGF401 treated animals than with the FGF401-CHO combination in some 
phases of the study, there was no consistent change and the results overall did not clearly correlate with the 
observed FGF401-related increases in ALT. Only one animal showed a minimal to mild increase in plasma 
miR-122 on FGF401 treatment that was associated with increased ALT levels, which might point towards 
a hepatic origin of the ALT in that specific animal. Interestingly, the same animal had among the highest 
levels of plasma TLCA upon FGF401 treatment, which is a highly hepatotoxic BA in experimental animals 
(29) and may have affected the membrane integrity and caused leakage from hepatocytes. In humans, TLCA 
and GLCA are efficiently sulfated at C-3 position which prevents their reabsorption from the intestine and 
leads to excretion in feces (29).  
A number of publications show increased serum liver enzyme levels in the absence of liver injury, and 
various potential mechanism have been investigated (32, 33). To address whether FGFR4 pathway 
inhibition led to upregulation of the Gpt gene coding for ALT in the liver, we performed gene expression 
analysis by RT qPCR in the 4-week dog study but did not observe any FGF401-related changes. 
Increased serum enzyme levels without signs of hepatic or skeletal muscle injury can be due to reduced 
Kupffer cell-mediated clearance of serum enzymes (34, 35). Kupffer cells are resident macrophages lining 
the hepatic sinusoids that clear several serum enzymes by phagocytosis and endocytosis, including 
creatinine kinase and aminotransferases. It was shown that reducing the number of Kupffer cells, e.g. by 
neutralizing macrophage colony-stimulating factor via an antibody, led to increased serum enzymes levels 
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without evidence of tissue injury. Interestingly, Kupffer cells express the BA receptor TGR5 and are 
functionally suppressed in the presence of hydrophobic BAs, which transiently attenuate their phagocytotic 
activity (36, 37). The potency of BAs on the TGR5 receptor is ranked in the order LCA ≥ DCA > CDCA > 
CA, with a stronger activation potential for the corresponding T-conjugated BAs TLCA ≥ TDCA > TCDCA 
> TCA (12). Notably, the results of our investigative dog study with FGF401 and co-administration with 
CHO indicates an association between FGF401-mediated increases in serum ALT activity and increases in 
BAs, predominantly with the secondary BAs of high hydrophobicity such as TLCA and TDCA. Thus, it 
could be speculated that the transient increase in serum ALT activity without signs of liver injury might 
have been caused by a transient reduction of phagocytotic Kupffer cell activity due to increased activation 
of the TGR5 receptor by TLCA and TDCA, leading to decreased clearance. Such a mechanism would be 
consistent with the observed association between increases in circulating ALT and the secondary BAs 
TLCA, TDCA in dogs after treatment with FGF401 and the possibility to mitigate this effect by CHO.  
 
Liver sinusoidal endothelial cells (LSEC) are also involved in the clearance of serum enzymes and 
immunoglobulins by endocytotic uptake (38-40) and are responsive towards specific BAs by expressing 
the TGR5 receptor (41). Whether TGR5 and thus BAs are directly involved in the regulation of the 
endocytotic activity of LSECs has not been investigated by our group. For LSECs, differences in the 
clearance kinetic and specificities for serum enzymes have been reported (38, 40). This could explain why 
different serum aminotransferases are differently affected by changes in BAs concentrations. Considering 
their localization within the sinusoid, both LSECs and Kupffer cells are exposed to high concentrations of 
secondary, hydrophobic BAs from the portal blood after intestinal reabsorption, and thus with high local 
abundance of their primary TGR5 ligands at their cell surface. However, further investigations are 
necessary to characterize such a mechanism, which could also co-occur with minimally increased 
hepatocyte leakage due to the presence of hydrophobic BAs and undetected in histopathology. 
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In conclusion our data showed that co-administration of the BA sequestrant cholestyramine prevented and 
reversed FGF401-mediated increases in serum ALT and may have utility to mitigate serum transaminase 
elevations in the clinic in instances of BA involvement, independent of its use for diarrhea management. 
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Methods 
Animals and treatment. For the 4-week toxicity study, male and female beagle dogs obtained from 
Marshall BKU Ltd (Grimston, UK) were approximately 10 months to 12 months of age, and weighed 5.7 
to 10.2 kilograms at the initiation of dosing. In this study, FGF401 was administrated as a solution of 100 
mM citrate buffer, pH 2.5, by oral gavage to groups of 3 or 5 dogs per sex at dosages of 0 (vehicle), 5, 15 
and 45 mg/kg/day using a dosage volume of 5 mL/kg. After cessation of treatment, two animals per sex 
in the control and high-dose group were maintained on the study for a 4-week recovery period.  
For the non-terminal investigative study, male beagle dogs obtained from Marshall BioResources 
(North Rose, NY), were approximately 7 months to 3 years of age, and weighed 7.2 to 11.1 kilograms 
at the initiation of dosing. FGF401 and cholestyramine (CHO; Questran Powder [Cholestyramine for Oral 
Suspension, USP]; NDC no. 49884-09366-66; lot no. 26079601; PAR Pharmaceutical Companies, Inc., 
Spring Valley, NY, USA) were each administered by oral gavage to beagle dogs as a formulation in their 
respective vehicles [FGF401, in 100 mM citrate buffer, pH 2.5; CHO, in drinking water]. The dose volume 
for the FGF401 formulation was 5 mL/kg. For CHO, the dosing aliquot was administered in 75 mL 
drinking water. For the investigative dog study, an initial feasibility study phase was conducted to 
investigate potential effects of CHO on the tolerability and exposure profile of FGF401. For this purpose, 
6 stock animals were administered FGF401 at a single dose of 5 mg/kg, followed by dosing with vehicle 
to CHO (first 3 animals) or CHO at 5 g/dog, corresponding to 11.25 g Questran powder (last 3 animals), 
approximately 2 hours later. Food was presented after the second dosing event. Blood was collected for 
determination of FGF401 plasma concentrations at approximately 0.5, 1, 3, 7 and 24 hours after FGF401 
administration. Animals were returned to colony on day 2. For the main study phase of the investigative 
study, a crossover design was applied similarly to a clinical setting in order to identify non-, weak or strong 
responders to FGF401 treatment and to follow-up on the time-course of FGF401-induced effects after 
CHO intervention with different biomarkers in relation to systemic exposure on an individual basis. Two 
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groups of 6 naïve animals were used (Group 1 with animal nos. 1006 to 1006 and Group 2 with animal 
nos. 2001 to 2006). The main study phase started with dosing of either vehicle or CHO at 5 g/animal 
for one week (phase I). FGF401 dosing at 5 mg/kg/day was initiated on study day 8 (phase II), followed 
approximately 2 hours later by a second administration of either vehicle or CHO (5g/animal) at each day. 
Food was presented to the animals after the second daily dosing event. Animals were not dosed on 
s tudy days 15-24 (washout/recovery period, phase III). Dosing with FGF401/CHO was restarted on 
s t u d y  d ay 25 ( p h a s e  IV )  and the dose groups crossed over on s t u d y  d ays 39-44 (phase V), with 
the last day of dosing on study day 44. The animals were returned to colony on study day 53. The 
administration schedule including cross-over design is shown in Figure 11. 
Clinical observations, body weight and food consumption. Daily clinical observations, once- or twice-
weekly body weights, and daily food consumption determinations were performed. 
Clinical pathology: In the 4-week dog toxicity study, blood samples for clinical chemistry (e.g. serum 
ALT, AST, total cholesterol) were collected once before initiation of dosing (pretest), on treatment days 
2, 8, 15, 22, and 26 approximately 24 hours postdose, and on days 3, 8, 15, and 26 of the treatment-free 
recovery period. In the investigative dog study, blood samples for clinical pathology assessments were 
collected once during pretest (hematology, clinical chemistry, and coagulation) for both the feasibility 
study phase and the main study phase. For the main study phase, blood sampling for clinical chemistry 
was conducted at approximately 3 hours postdose (post vehicle, CHO or FGF401 dosing, as appropriate, 
or at similar time of the day during washout periods) on study days 1, 3, 7, 8, 11, 14, 15, 18, 21, 23, 25, 
28, 31, 35, 38, 42, and 45.  
Toxicokinetics: Plasma samples for toxicokinetic (TK) analysis were collected from all animals 
approximately 0.5, 1, 3, 7, and 24 hours post FGF401 dosing on study days 1 and 26 of the 4-week toxicity 
study, as well as in the single-dose feasibility phase and in the main study phase on study days 8, 14, 25, 
39 and 44 of the investigative study. 
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C4/BA profiling by LC-MS. Plasma samples for BA profiling and C4 analysis were collected on study 
days 1 and 26 concurrent to TK sample collection in the 4-week toxicity study, and in the investigative 
study during the main study phase concurrent with clinical chemistry and TK. Feces samples for BA 
analysis were collected at the end of treatment week 4 in the 4-week study, and in the investigative study 
at pretest and on study days 7 and 49 of the main study phase. BA profiles and C4 analyses were carried 
out on an Agilent 1290 Infinity ultra high-performance liquid chromatography (UPLC) system interfaced 
to an ABSciex API4000 triple-quadrupole tandem mass spectrometer (LC-MS/MS) operated in positive 
electrospray ionization mode. All data were acquired and analyzed using Analyst 6.1 data processing 
software. Reference standards and deuterated internal standards (IS) for calibration and quantification 
were obtained from Sigma-Aldrich (CA, CDCA, DCA, LCA, TCDCA, d4-CA, d4-CDCA, d4-LCA), 
Steraloids (TLCA, d4-DCA), Calbiochem (TCA, TDCA), C/D/N Isotopes (d4-UDCA, d4-GCA, d4-
GCDCA, d4-GUDCA) and Toronto Research Chemicals (C4 and d7-C4). All other chemicals and 
reagents were purchase from Sigma-Aldrich and were of the highest purity available. Stock solutions for 
BA and IS were prepared in methanol (MeOH, 10 mM), combined and diluted to obtain mixed working 
solutions for BAs and IS at concentrations of 100 µM, each. Calibration standards for analysis of plasma 
samples were prepared by spiking defined volumes of serially diluted BA working solutions to 50 µL of 
aqueous 20% bovine serum albumin solution (BSA, fatty acid free). Quality control (QC) samples were 
prepared in control mouse, rat and dog plasma containing a low, mid and high concentration of each 
analyte. Plasma samples (50 µL), QCs and calibration standards were processed by addition of 50 µL of 
mixed IS working solution and 450 µL acetonitrile (ACN) and thoroughly mixed. Samples were 
centrifuged at >14’000 × relative centrifugation force (rcf) for 15 min at 4ºC, the supernatants were 
transferred into new tubes and evaporated to dryness in a vacuum centrifuge. After reconstitution in 60 
µL MeOH/water 1:1 (v/v) containing 0.1% formic acid (FA), 5 µL were injected into the LC-MS/MS 
system for analysis. For BA analysis in feces, a multi-step extraction procedure was applied using solvents 
with different polarities and acidification according to a protocol by Manes et al. (42) with modifications, 
to enable BA extraction both from naïve and CHO containing feces. An aliquot of approximately 2 g of 
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fecal sample was accurately weighed in a glass flask, diluted 1:10 (w/w) in water, mixed and allowed to 
soak/swell at 4°C. The samples were thoroughly mixed to obtain a homogenous slurry. Two mL of the 
homogenous slurry (corresponds to 200 mg fecal samples) were transferred into a weighed 15 mL plastic 
tube and centrifuged at 5’000 x rcf for 10 min. The supernatant was removed, transferred into a new 
tube, and later combined with the extracts of the 4 subsequent extraction steps of the residual pellet, 
which were as follows: 4 mL of MeOH, 4 mL of ACN and 2 x 4 mL of acidified ethanol containing 0.5 
N hydrochloric acid (HCl). An aliquot (900 μL) of the combined extracts was transferred into a new 
tube, spiked with IS, mixed, and evaporated to dryness in a vacuum centrifuge. After reconstitution in 
500 µL MeOH/water 1:1 (v/v) containing 0.1% FA, 5 µL were injected into the LC-MS/MS system for 
analysis. Calibration standards were prepared by spiking defined volumes of serially diluted BA working 
solutions to a mixture of MeOH:ACN:water 4:4:1 to reflect a similar solvent constitution as in the samples, 
evaporated to dryness in a vacuum centrifuge and  reconstituted in 500 μL methanol/water 1:1 (v/v) 
containing 0.1% FA for LC-MS/MS analysis. The dry weight of the fecal samples was determined by 
drying the residual pellet after extraction to constant weight. 
 
microRNA analysis (miR-122). Plasma samples for microRNA analysis were collected from all animals 
during the main study phase of the investigative study time-matched with clinical chemistry sample 
collection. MicroRNA analysis was performed according to a protocol published by Thompson and 
coworkers (43). Small RNA was extracted from 50 µl of plasma by using the miRNeasy/MinElute kit and 
following the instructions of the manufacturer (Qiagen). Elution of small RNA was conducted in 14 µl of 
nucleic acid-free water. 3.2 µl of eluted small RNA was reverse transcribed into cDNA by using the 
Megaplex RT primer human pool A and B and the Taqman MicorRNA Reverse Transcription kit (Applied 
Biosystems / Life Technologies, reference 4366596), following the instructions of the manufacturer. 2.5 µl 
of cDNA was preamplified by using the Megaplex Preamp primer human poolA and B (Applied Biosystems 
/ Life Technologies, reference 4399201 and 4399233) and the Taqman PreAmp Master mix (Applied 
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Biosystems / Life Technologies, reference 4391128), following the instructions of the manufacturer. The 
microRNA miR-122 was amplified from preamplified cDNA by using a commercially available validated 
Taqman assay (reference 002245) diluted in the Taqman MasterMixII (Applied Biosystems / Life 
Technologies), following the instructions of the manufacturer. The relative quantification of plasmatic 
microRNA levels was performed using the standard curve method to generate expression values as number 
of molecules.  
 
Analysis of mRNA expression in liver. Liver samples for mRNA levels analysis were collected at scheduled 
necropsy at approximately 4 hours post last FGF401 dose administration in the 4-week toxicity study and 
immediately snap frozen in liquid nitrogen. Total RNA was extracted by acid guanidinium thiocyanate-
phenol-chloroform extraction (Trizol, Invitrogen Life Technologies) from each frozen tissue section and 
the total RNA was purified on an affinity resin (Rneasy, Qiagen) according to the manufacturer’s protocol. 
Total RNA was quantified by the absorbance at λ = 260 nm (A260nm), and the purity was estimated by 
the ratio A260nm/A280nm. RNA integrity was controlled by running a Bioanalyzer profile (Agilent). RNA 
was stored at -80°C until analysis. 300 ng of total RNA was reverse transcribed into cDNA by using the 
High Capacity cDNA Archive Kit according to the manufacturer protocol (Applied Biosystems). PCR was 
performed in triplicate from 6 ng of cDNA by using the SYBR Green Real-time PCR master mix following 
the instructions of the manufacturer (Applied Biosystems). Quantification of gene expression changes was 
performed by using the standard curve method. 18S RNA values were used for normalization and data 
from technical triplicate were averaged. Sybrgreen assays were either purchased from Qiagen (18S 
#QT00199367, Gpt #QT01353142) or designed and validated in house as for Cyp7a1 (Cyp7a1 forward 
primer: CAGGCCTCCCCATTCATGT, Cyp7a1 reverse primer: AAGCCCTCTGCCAGCTTTTC). 
Statistics. 
GraphPad Prism 7.03 (GraphPad Software) was used for statistical analysis. Data are expressed as mean 
± SEM. Differences among multiple groups were examined using one-way ANOVA with Dunnett’s 
multiple comparison test versus control group. Differences between two groups were evaluated using an 
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unpaired, 2-tailed Student’s t test. P values below 0.05 were considered significant. TIBCO Spotfire was 
used for correlation analysis by linear regression, principal component analysis (PCA) was performed 
with prcomp function in R( version 3.4.1). 
Study approval and animal welfare. 
These studies were performed in accordance to the respective national animal welfare regulations and 
approved animal study licenses. The 4-week toxicity dog study was conducted in accordance with the 
requirements of the UK law (Animals (Scientific Procedures) Act 1986). The non-terminal investigative 
dog study was conducted in accordance with the United States Department of Agriculture Animal 
Welfare Regulations and with the Novartis Animal Care and Use Committee-approved protocol no. TX 
4039. 
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Figures 
Figure 1: Schematic overview of the FGF19/FGFR4/KLB regulated hepatic BA biosynthesis, conjugation, 
transport and enterohepatic cycling. Binding of FGF19 to the FGFR4/KLB receptor complex in the liver 
results in repression of Cy7a1 transcription, the rate limiting step in BA biosynthesis. Intestinal FGF19 
expression in enterocytes is regulated by FXR, a nuclear transcription factor which is activated by 
intestinally reabsorbed BAs. By this feedback loop, BAs regulate their own biosynthesis. In contrast, 
inhibition of FGFR4 by FGF401 leads to transcriptional activation of Cyp7a1 in the liver and thus to BA 
biosynthesis. Hepatic Cyp7a1 activity can indirectly be monitored in a non-invasive way by the blood 
marker C4, which is an intermediate in BA biosynthesis and used as surrogate PD readout for FGFR4 
inhibition in the present dog studies.  
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Figure 2: PD of FGFR4 inhibition in the 4-week FGF401 dog study. Dogs were treated by oral gavage with 
the FGFR4 inhibitor FGF401 for 4 weeks at doses of 5, 15 and 45 mg/kg/day or with vehicle. (A) 
Upregulation of Cyp7a1 mRNA transcript confirms blockage of FGFR4 by FGF401; N = 6 in each group. 
(B, C) Circulating 7α-hydroxy-4-cholesten-3-one (C4), a marker for hepatic Cyp7a1 activity and included 
as surrogate PD readout for FGFR4 inhibition, is increased in plasma after a single dose (B) and repeated 
daily dosing of FGF401 for 4 weeks (C), confirming antagonism on FGFR4. Area under the curve (AUC0-
24h) values were calculated for C4 based on individual plasma concentrations determined in samples 
collected 0.5, 1, 3, 7, and 24 hours post dose. N = 10 for vehicle control and 45 mg/kg/day groups, n = 6 
for 5 and 15 mg/kg/day groups. (A, B, and C) Mean ± SEM are shown. *P < 0.05, ** < 0.01, and *** < 
0.001, *** < 0.0001 by one-way ANOVA with Dunnett’s multiple comparison test versus control group. 
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Figure 3: Bile acids in plasma and feces in the 4-week FGF401 dog study. (A, B) Relative BA composition 
in plasma (A) and feces (B) of control male and female dogs. (C, D) Treatment with FGF401 for 4 weeks 
at doses of 5, 15 and 45 mg/kg/day resulted in increases in BA components in (C) plasma (TCA, TDCA, 
TCDCA, TLCA; n = 10 for vehicle control and 45 mg/kg/day groups, n = 6 for 5 and 15 mg/kg/day groups.) 
and their corresponding unconjugated BAs in (D) feces (CA, DCA, CDCA, LCA; n = 8 for vehicle control, 
n = 5 for 5 and 15 mg/kg/day, and n = 9 for 45 mg/kg/day groups), respectively. (C) Area under the curve 
(AUC0-24h) values were calculated based on individual plasma BA concentrations determined in samples 
collected 0.5, 1, 3, 7, and 24 hours post dose. (C, D) Mean ± SEM are shown. *P < 0.05, ** < 0.01, and 
*** < 0.001, *** < 0.0001 by one-way ANOVA with Dunnett’s multiple comparison test versus control 
group.  
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B
C
A Figure 4: Changes in total 
cholesterol, serum alanine and 
aspartate aminotransferases in the 4-
week FGF401 dog study. Treatment 
with FGF401 at doses of 5, 15, and 
45 mg/kg/day resulted in (A) 
decreases in total cholesterol, (B) 
reversible, minimal to moderate 
increases in serum alanine 
aminotransferase activity, and (C) 
minimal increases in serum aspartate 
aminotransferase activity. (A, B, C) 
N = 10 for vehicle control and 45 
mg/kg/day groups during the 
treatment period, and n = 2 during 
recovery period; n = 6 for 5 and 15 
mg/kg/day groups. Mean ± SEM are 
shown. One-way ANOVA with 
Dunnett’s multiple comparison test 
versus vehicle control group. 5 
mg/kg/day group: * p < 0.05, ** p < 
0.01; 15 mg/kg/day group: # p < 
0.05, ## p < 0.01; 45 mg/kg/day 
group: $ p < 0.05, $$ p < 0.01, $$$ p 
< 0.001, $$$$ p < 0.0001. 
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Figure 5: Investigative dog study with FGF401 and cholestyramine. Crossover study design of the 
investigative dog study with 5 mg/kg/day FGF401 administration and co-administration of the BA 
sequestrant cholestyramine (CHO, 5 g per animal). In phase I, the effect of CHO on BAs and clinical 
chemistry parameters was assessed. In study phases II and V, group 1 animals were daily treated with 
FGF401 (vehicle to CHO was water), while group 2 animals were daily treated with FGF401 and CHO 
(approximately 2 hours post FGF401 administration). Phase IV consisted of a treatment crossover, phase 
III and VI were washout/recovery phases without any treatment. N = 6 per group. 
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Figure 6: Changes in ALT in investigative dog study with FGF401 and cholestyramine. Treatment with 
CHO did not affect serum ALT levels (phase I study days 1 to 7). Treatment with 5 mg/kg/day FGF401 
alone resulted in minimal to moderate increases in serum ALT activity (group 1: phase II study days 8 to 
14 and phase V study days 39 to 44; group 2: phase IV study days 25 to 38), which could be mitigated and 
reversed by co-administration with the BA sequestrant CHO (group 2: phase II study days 8 to 14 and phase 
V study days 39 to 44; group 1: phase IV study days 25 to 38). Discontinuation of FGF401 treatment 
(recovery/washout phases III study days 15 to 24 and phase VI study day 45 onwards) or administering 
CHO on FGF401 (group 2: crossover from phase IV to phase V) rapidly decreased ALT levels to pretest 
control values. N = 6 per group. Mean ± SEM are shown. 
 
 
 
 
 
 
30 
 
Figure 7: Effect of the BA sequestrant CHO on BAs in feces and plasma of dogs. (A) Administration of 5 
grams of CHO to dogs by oral gavage led to increased fecal excretion of BAs as determined by BA content 
in fecal samples. (B) Increased fecal excretion of BAs was associated with decreased BA concentrations in 
the plasma and most pronounced for the secondary BAs DCA, LCA in feces and their corresponding 
conjugates TDCA, TLCA in plasma. N = 6 per group. Mean ± SEM are shown. *P < 0.05, ** < 0.01, and 
*** < 0.001, by students t test group 1 versus group 2 
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B
C
A Figure 8: Changes in plasma 
BAs in investigative dog 
study with FGF401 and 
cholestyramine. (A) 
FGF401-mediated increases 
in plasma BAs at doses of 5 
mg/kg/day could be 
mitigated and reversed by 
co-administration with the 
BA sequestrant CHO. (B) 
Primary T-conjugated 
(taurine) BAs in plasma 
(TCA, TCDCA). (C) 
Secondary T-conjugated 
BAs in plasma (TLCA, 
TDCA), for which CHO –
mediated reductions 
appeared to be slightly more 
pronounced. N = 6 per group. 
Mean ± SEM are shown. *P 
< 0.05, ** < 0.01, and *** < 
0.001, by students t test 
group 1 versus group 2. 
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Figure 9: Effect of FGF401 and cholestyramine on circulating cholesterol and C4. (A) Deceases in serum 
total cholesterol in dogs when treated with CHO or FGF401 alone, or under co-administration thereof. (B) 
Increases in plasma C4 in dogs when treated with CHO or FGF401 alone, indicating induction of hepatic 
Cyp7a1. Co-administration of CHO and FGF401 to dogs resulted in additional effects on plasma C4 
elevation. N = 6 per group. Mean ± SEM are shown. *P < 0.05, ** < 0.01, and *** < 0.001, by students t 
test group 1 versus group 2. 
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Figure 10: Circulating miR-122 as marker for hepatocellular injury. Plasma miR-122 in the investigative 
dog study with FGF401 and cholestyramine did not show consistent treatment-related changes, except for 
some minimal increases in individual dogs of Group 2 when treated with FGF401 alone (phase IV study 
days 25 to 38) which was reversed by co-treatment with CHO (phase V study days 39-44). N = 6 per group. 
Mean ± SEM are shown. ** P < 0.01 by students t test group 1 versus group 2 
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